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OBJECTIVES The purpose of this study was to determine if left ventricular (LV) systolic dysfunction was
also a predictor of sudden cardiac death (SCD) in adults late after repair of tetralogy of Fallot
(TOF).
BACKGROUND Previous studies looking at risk factors for SCD in adults with repair of TOF have focused
on the right ventricle (RV).
METHODS A retrospective chart review of patients assessed at the Toronto Congenital Cardiac Centre
for Adults was performed. Twelve adult patients with repaired TOF and SCD were identified
(SCD group). A total of 125 living adult patients with repaired TOF were randomly selected
for comparison (control group).
RESULTS Patients with SCD were more likely to exhibit moderate or severe pulmonary regurgitation
(92% vs. 51%, p  0.02), have a history of sustained ventricular tachycardia (42% vs. 6%,
p  0.01), and have a QRS 180 ms (56% vs. 13%, p  0.02). Moderate or severe LV
systolic dysfunction was also significantly more common in patients with SCD than in the
control group (42% vs. 9%, p  0.01) with a positive predictive value of 29%. The
combination of moderate or severe LV systolic dysfunction and QRS 180 ms had a positive
and negative predictive value for SCD of 66% and 93%, respectively.
CONCLUSIONS Moderate or severe LV systolic dysfunction is significantly more common in adult patients
with repaired TOF and SCD. The combination of QRS180 ms and significant LV systolic
dysfunction has high positive and negative predictive value for SCD. The implication of the
role of prophylactic antiarrhythmic implantable cardiac defibrillator insertion in these patients
needs further elucidating. (J Am Coll Cardiol 2002;40:1675–80) © 2002 by the American
College of Cardiology Foundation
Intracardiac repair for tetralogy of Fallot (TOF), the most
common cyanotic congenital heart defect, has been per-
formed for over four decades with excellent long-term results
(1,2). Risk for late sudden cardiac death (SCD), however,
occurs in as many as 6% over 30 years of follow-up (3–15).
Several risk factors for the development of sudden death
have been suggested including severe pulmonary regurgita-
tion (PR), older age at repair, transient complete heart block
postoperatively, increased right ventricular (RV) pressure
after repair, ventricular premature contractions, late onset of
complete heart block, and, more recently, QRS duration
180 ms (3–15). Indeed, increased QRS width has been
shown to correlate with RV dilation and the propensity for
sustained ventricular arrhythmia and SCD (4,15). Although
some of these may be sensitive predictors, most of these risk
factors have a rather low positive predictive value (3–15)
and, as such, cannot be relied on to predict SCD. Further
risk stratification is required in this patient population
before intervention to prevent SCD can be recommended.
Left ventricular (LV) systolic dysfunction is an indepen-
dent predictor for SCD in patients with ischemic and
idiopathic dilated cardiomyopathy (16–19). We hypothe-
sized that LV systolic dysfunction may play a role in SCD
in adults patients with repaired TOF. The purpose of this
study was to evaluate the prevalence of LV systolic dysfunc-
tion in these patients and assess its value in predicting SCD.
METHODS
Patient population. Adult patients (18 years old) with
SCD were identified by a retrospective chart review per-
formed on all patients with repaired TOF assessed at the
Toronto Congenital Cardiac Centre for Adults (TCCCA).
Sudden cardiac death was defined as a natural but unex-
pected death due to cardiac causes, heralded by abrupt loss
of consciousness within 1 h of the onset of acute symptoms
(20). As the purpose of this study was to examine for late
events, patients who did not survive beyond 30 days after
the initial TOF repair were excluded. Of the 602 living
patients with repaired TOF listed in the TCCCA comput-
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erized database, 292 were excluded because they did not
have complete follow-up data (i.e., echocardiogram or
electrocardiogram) as they were not followed serially by the
TCCCA. Of the remaining 310 living patients, every
second patient from the alphabetized list was selected until
it was judged that a large enough control group had been
assembled (n  125).
Baseline information including demographics and operative
reports was obtained from the patient’s medical records. New
York Heart Association (NYHA) class, symptoms, clinical
events, and medication intake were obtained from the latest
clinical visit note in all patients. The research ethics board of
the Toronto General Hospital approved this study.
Electrocardiographic measurements. QRS duration for
all patients was analyzed manually from their latest standard
(25 mm/s and 1 mV/cm) resting 12-lead electrocardio-
grams. QRS duration was defined as the maximal QRS
length in any lead from the first inflection to the final sharp
vector crossing the isoelectric line. Electrocardiographic
data from patients who were paced were excluded from the
QRS analysis (4).
Echocardiographic analysis. Data from the patient’s most
recent transthoracic echocardiogram before their SCD or
latest clinical visit were reviewed by an experienced echo-
cardiographer. The degree of pulmonary, tricuspid, mitral,
and aortic regurgitation as well as RV dilation, RV and LV
systolic function was recorded. The magnitude of valvular
regurgitation was graded as none, mild, moderate, or severe
using color and Doppler flow criteria (21,22). Right ven-
tricular dilation was estimated from RV inlet measurements
made at end-diastole from apical four-chamber view (23).
Right ventricular enlargement was considered mild when
the RV inlet measured between 40 and 50 mm, moderate
when it was between 50 and 60 mm, and severe when it was
60 mm. Systolic function of the LV on echocardiography
was visually assessed and recorded as normal (ejection
fraction [EF] 60%), mildly reduced (EF  40% to 59%),
moderately reduced (EF  20% to 39%), and severely
reduced (EF 20%) (24).
Statistical analysis. Statistical calculations were performed
using the SPSS package (SPSS for Windows, Base System
User’s Guide, Telease 10.0 Chicago: SPSS, 2000). Data
were presented as mean 1 SD where appropriate. Patients
were classified into two groups based according to the
occurrence of SCD. Fisher exact or chi-square tests were
used to compare categorical variables, as appropriate. Stu-
dent t tests were used for comparisons of continuous
variables. Kaplan-Meier survival curve was used to estimate
survival of patients with and without moderate or severe LV
systolic dysfunction, and a log-rank test was used to com-
pare survival between these two groups. Significance was set
at 0.05 (two-sided).
RESULTS
Patients. A total of 602 patients with repaired TOF were
identified from the TCCCA database. Twenty-seven pa-
tients (4%) were known to have died. Of these, 15 patients
were excluded from the study: four had died from postop-
erative complications within 30 days after their TOF repair,
five died from noncardiac causes (two from motor vehicle
accident, two from cancer, one from liver dysfunction), five
died from nonsudden cardiac causes (four from progressive
congestive heart failure and one from infective endocardi-
tis), and one died from an SCD before any investigations
Table 1. Sudden Cardiac Death Group Characteristics
Patient
Age at
SCD
Place of
SCD
Outcome of
SCD
History of
Arrhythmia
Arrhythmia
Medications
Autopsy
Results
1 73 Out of Hospital Death None None NA
2 37 Out of Hospital Death Atrial flutter and VT Amiodarone ? arrhythmia
3 24 Out of Hospital Death Atrial flutter Digoxin ? arrhythmia
4 45 Out of Hospital Death None None NA
5 33 Out of Hospital Death None None ? arrhythmia
6 57 Out of Hospital Resuscitated* VT Amiodarone NA
7 54 Out of Hospital Death None Digoxin NA
8 29 Out of Hospital Death WPW Digoxin and Propatenone ? arrhythmia
9 24 Out of Hospital Death None None ? arrhythmia
10 47 Out of Hospital Resuscitated* VT Sotalol NA
11 62 Hospital† Death Atrial flutter Amiodarone NA
12 70 Hospital† Death SVT and VT Amiodarone NA
*Patients subsequently had a pulmonary valve replacement with ventricular cryoablation and AICD insertion; †hospitalized for congestive heart failure but clinically stable at time
of death.
AICD  antiarrhythmic implantable cardiac defibrillator; NA  not available; SCD  sudden cardiac death; SVT  supraventricular tachycardia; VT  ventricular
tachycardia; WPW  Wolff Parkinson White.
Abbreviations and Acronyms
EF  ejection fraction
LV  left ventricle or left ventricular
NYHA  New York Heart Association
PR  pulmonary regurgitation
RV  right ventricle or right ventricular
SCD  sudden cardiac death
TCCCA  Toronto Congenital Cardiac Centre for
Adults
TOF  tetralogy of Fallot
VT  ventricular tachycardia
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could be performed. The study group thus comprised 12
patients (2%) with SCD (two resuscitated from SCD and
alive, 10 deceased) (Table 1) and a control group of 125
living patients. Forty-seven (34%) of these patients (eight
from the SCD group and 39 from the control group) were
previously reported in other studies (15,25).
Demographic and surgical data are presented in Table 2.
There was no significant difference between the two groups
in terms of the era of surgical repair and age at last follow-up,
although a trend towards older age at repair was noted in the
SCD group (20  21 years vs. 13  13, p  0.07).
Clinical outcome. Clinical data are presented in Table 3.
The SCD group was more symptomatic with a significantly
higher incidence of dyspnea, orthopnea, palpitations,
edema, pre-syncope/syncope, and sustained ventricular
tachycardia (VT) compared with the living control group.
Diuretics, angiotensin-converting enzyme inhibitors, anti-
arrhythmics, and anticoagulants/antiplatelets were also pre-
scribed more commonly in the SCD group. Eight patients
(67%) in the SCD group were prescribed antiarrhythmics.
The majority were receiving amiodarone alone (4 patients)
or digoxin alone (2 patients), one patient used sotalol (1
patient), and one patient was prescribed propafenone and
digoxin (1 patient).
Electrocardiographic data. Electrocardiographic data
were recorded in 132 of 137 patients (three patients in the
SCD group and two in the control group were excluded due
to paced rhythms). Mean QRS duration was significantly
greater in the SCD group compared with controls (170 
14 vs. 153  21 ms, p  0.02), and a QRS duration 180
ms was significantly more common in the SCD group
compared with the control group (56% vs. 13%, p  0.02).
Echocardiographic features. Echocardiographic data are
presented in Table 3. Patients with SCD had a greater
incidence of moderate-to-severe PR as well as a trend
toward moderate-to-severe RV dilation (92% vs. 51%, p 
0.02 and 54% vs. 32%, p 0.09, respectively). Furthermore,
patients with SCD had a significantly higher incidence of
moderate or severe LV systolic dysfunction when compared
with the control group (42% vs. 9%, p  0.01). When
patients who had paced rhythms at their latest echocardio-
gram were excluded, the aforementioned statistically signif-
icant difference in the incidence of moderate or severe LV
systolic dysfunction between the SCD and control group
was still present (33% vs. 7%, p  0.01). In addition, there
was no significant difference in the incidence of moderate or
severe LV systolic dysfunction in patients with normal-to-
mild RV dilation or moderate-to-severe RV dilation (10%
vs. 15%, p  0.40). The positive and negative predictive
value of moderate or severe LV systolic dysfunction for
SCD was 29% and 94%, respectively. When combined with
QRS 180 ms, the positive and negative predictive value
for SCD was 66% and 93%, respectively.
Survival analysis. In a Kaplan-Meier analysis, moderate or
severely impaired LV systolic function was associated with a
greater mortality (p  0.01) (Fig. 1).
DISCUSSION
The present study provides, for the first time, evidence that
moderate or severe LV systolic dysfunction is an important
predictor of SCD in adult patients late after TOF repair.
The combination of moderate or severe LV systolic dys-
function and QRS 180 ms had a high positive and
negative predictive value for SCD.
RV. Previous studies of risk factors for SCD in adults with
repaired TOF have focused on RV hemodynamics. Signif-
icant PR has been associated with RV dilation, and, more
recently, a mechanoelectric relationship between increased
QRS duration and RV dilation has been demonstrated. In
fact, in adult patients with repaired TOF, a QRS duration
180 ms has been found to be predictive of sustained VT
and SCD (4,15). It is believed that RV myocardial stretch
engenders areas of inhomogeneous electrical activity
(25,26), predisposing to the development of ventricular
arrhythmia (4,26–28). In our study we corroborated the
association of SCD with significant PR, sustained VT, and
QRS width 180 ms. A trend toward moderate-to-severe
RV dilation in the SCD group was shown but did not reach
statistical significance. The qualitative nature of two-
Table 2. Demographic and Surgical Data for the SCD and
Control Groups
SCD Group
(n  12)
Control Group
(n  125)
p
Value
Male 9 (75%) 71 (57%) 0.36
Palliative surgery
BT shunt 5 (42%) 63 (50%) 0.76
Mean age (yrs)* 5  5 4  7 0.10
Tetralogy repair
Surgical era 1950s–1970s 7 (58%) 79 (63%) 0.76
Surgical era 1980s–2000s 5 (42%) 46 (37%) 0.76
Mean age at repair (yrs) 20  21 13  13 0.07
Transannular patch 7 (58%) 67 (54%) 1.00
Co-morbidities
Coronary artery disease 2 (17%) 4 (3%) 0.09
Re-operations 6 (50%) 52 (42%) 0.76
Mean number per patient 0.62 0.50 0.53
Mean age (yrs) at last surgery† 43  19 29  17 0.15
Surgery type
Resection of aneurysm 1 (8%) 1 (1%) 0.17
Pulmonary valve replacement 4 (33%) 27 (22%) 0.47
Relief of RVOTO 0 (0%) 22 (18%) 0.21
Closure of residual shunts 3 (25%) 10 (8%) 0.11
Mitral valve replacement 2 (17%) 0 (0%) 0.09
Aortic valve replacement 0 (0%) 3 (2%) 1.00
Tricuspid valve surgery 2 (17%) 7 (6%) 0.18
Atrial cryoablation 0 (0%) 6 (5%) 1.00
Ventricular cryoablation 0 (0%) 1 (1%) 1.00
Maze procedure 0 (0%) 2 (2%) 1.00
CABG 1 (8%) 1 (1%) 1.00
Last follow-up
Mean age (yrs) 45  18 38  14 0.10
Mean time (yrs) from repair 21  9 25  9 0.13
*Data available for 68 patients; †Data available for 58 patients.
BT  Blalock-Taussig; CABG  coronary artery bypass surgery; RVOTO 
right ventricular outflow tract obstruction; SCD  sudden cardiac death.
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dimensional transthoracic echocardiography and its lack of
precision in assessing RV size is well known and probably
accounts for our findings. QRS duration, a more quantifi-
able and reproducible measure of RV size (29), was indeed
significantly prolonged in our SCD group. It is clear that
RV hemodynamics in adult patients with repaired TOF play
a major role in the pathophysiology of SCD, but we think
that RV hemodynamics may constitute only part of the
problem.
LV. In our study moderate or severe LV systolic dysfunc-
tion was demonstrated to be a strong predictor in SCD. The
etiology of LV systolic dysfunction in our cohort of patients,
however, remains unclear. The era of intracardiac repair did
not differ between the two groups, making poor myocardial
protection at the time of repair an unlikely culprit. A trend
toward older age at intracardiac repair in our SCD group,
however, was observed. Older age at repair, with longer
periods of volume overload and chronic hypoxemia, may, in
part, explain the degree of LV dysfunction seen in these
patients (26). Of note, older age at repair was previously
found to be a predictor of LV systolic dysfunction in a study
reported by Hausdorf et al. (30), but data on the incidence
of SCD in these patients was not provided.
Patients in our SCD group had clearly been more
symptomatic over the duration of follow-up, with an in-
creased incidence of dyspnea, arrhythmias, and syncope
(evidence supportive of our findings of LV systolic dysfunc-
tion on echocardiography), but were all clinically stable with
appropriate medical therapy, with no difference in NYHA
class at the time of their sudden death.
In our study amiodarone was the single most prescribed
antiarrhythmic medication in the SCD group, a medication
that is known to protect from, and not to provoke, SCD
(31,32). Digoxin was also commonly prescribed as a stand-
alone medication (except in one case with propafenone),
and, while it is known to lower the ventricular fibrillation
threshold, it should not have caused an increased incidence
in SCD in our population as was shown with the Digoxin
Investigation Group (DIG) study (33).
Our hypothesis is that, while abnormal RV hemodynam-
ics with its associated RV stretch and scarring provide the
substrate for VT, it is the LV hemodynamics that ultimately
dictate the clinical outcome of such arrhythmias.
Given the high positive and negative predictive value of
moderate or severe LV systolic dysfunction and QRS180 ms
to predict SCD in adult patients with repaired TOF, the role
of prophylactic antiarrhythmic implantable cardiac defibrillator
insertion in these patients warrants further elucidating.
Table 3. Clinical Outcomes, Electrocardiographic and Hemodynamic Data for the SCD and
Control Groups
SCD Group
(n  12)
Control Group
(n  125)
p
Value
Symptoms
Dyspnea 7 (58%) 31 (25%) 0.03
Orthopnea 5 (42%) 15 (12%) 0.01
Palpitations 10 (83%) 41 (33%) 0.01
Presyncope or syncope 7 (58%) 14 (11%)  0.01
Edema 5 (42%) 16 (13%) 0.01
NYHA class  2 4 (33%) 18 (14%) 0.12
Atrial fibrillation or atrial flutter 3 (25%) 23 (19%) 0.74
Ventricular tachycardia 5 (42%) 7 (6%)  0.01
Medications
Anticoagulation/antiplatelets 7 (58%) 29 (23%) 0.05
Antiarrhythmic drugs 8 (67%) 18 (14%)  0.01
ACE inhibitors 5 (42%) 16 (13%) 0.02
Diuretics 6 (50%) 13 (10%)  0.01
Beta-blockers 2 (17%) 5 (4%) 0.05
ECG data
Number of patients with data 9 123 —
Mean (ms) QRS duration 170  14 153  21 0.02
QRS  180 ms 5 (56%) 16 (13%) 0.02
Echocardiographic data
Mean age (yrs) of last echocardiogram 43  18 38  14 0.58
Moderate or severe LV dysfunction 5 (42%) 11 (9%)  0.01
RV  mild dilation 7 (54%) 40 (32%) 0.09
Mean RVSP (mm Hg)* 46  19 44  13 0.54
PR  moderate 11 (92%) 64 (51%) 0.02
TR  moderate 6 (50%) 38 (30%) 0.38
MR  moderate 2 (17%) 7 (6%) 0.06
AR  moderate 0 (0%) 1 (1%) 0.87
*Data available for 90 patients only.
ACE  angiotensin-converting enzyme; AR  aortic regurgitation; ECG  electrocardiogram; LV  left ventricular;
MR  mitral regurgitation; NYHA  New York Heart Association; PR  pulmonary regurgitation; RV  right ventricle;
RVSP  right ventricular systolic pressure; TR  tricuspid regurgitation.
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Study limitations. This was a retrospective study and
includes only adult survivors who successfully made the
transition from a pediatric to an adult institution. The size
of the SCD group is small, and the study may lack the
power to determine a significant difference in ages of
palliation and surgical repair between the two populations in
the study. In addition, autopsy reports were not available for
all of the patients in the SCD group, and, thus, it is not
possible to ascertain that their deaths were solely arrhythmic
in nature. There are also limitations with echocardiographic
assessment of LV systolic function in this study, which was
determined by visual assessment by an experienced echocar-
diographer rather than by quantitative methods. However,
this limitation is minimized by the fact that visual assess-
ment of LV EF has been shown to be at least equal, if not
superior to, quantitative measurements of LV systolic func-
tion when performed by an experienced echocardiographer
(34). Symptoms of left-sided heart failure were also more
common in our SCD, which would support our echocar-
diographic assessment of LV systolic function. Of note,
much of the data reflect outcomes of operations that were
done in an earlier surgical era, and newer current surgical
strategies may diminish the incidence of LV systolic dys-
function and SCD in the future. This study, however, is
representative of the adult population with repaired TOF
that is being cared for at the present time, and our results do
apply to the current patient population.
Conclusions. Moderate or severe LV systolic dysfunction
is a risk factor for SCD and predicts survival in adult
patients with repaired TOF. The combination of moderate
or severe LV systolic dysfunction and QRS 180 ms had a
positive and negative predictive value for SCD of 66% and
93%, respectively. The implications of the role of prophy-
lactic antiarrhythmic implantable cardiac defibrillator inser-
tion in these patients need further elucidating.
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